Market Research Logo

Muscle Invasive Bladder cancer- Pipeline Insight, 2019

Muscle Invasive Bladder cancer- Pipeline Insight, 2019 report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Muscle Invasive Bladder cancer pipeline landscape is provided which includes the disease overview and Muscle Invasive Bladder cancer treatment guidelines. The assessment part of the report embraces, in depth Muscle Invasive Bladder cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Muscle Invasive Bladder cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Muscle Invasive Bladder cancer Understanding
According to the Urology Care Foundation, Muscle invasive bladder Cancer (MIBC) is a cancer that spreads into the detrusor muscle of the bladder, which is a thick muscle deep in the bladder wall. The bladder wall has many layers, made up of different types of cells. This cancer is more likely to spread to other parts of the body and about 1 out of 4 people who get bladder cancer in the United States have the muscle-invasive kind. The causes for developing muscle invasive bladder cancer involves tobacco or other cancer-causing agents such as an exposure of inappropriate radiation beams that are focused on the pelvis during chemotherapy. Most bladder cancers start in the urothelium or transitional epithelium, which is the inside lining of the bladder. Transitional cell carcinoma is cancer that forms in the cells of the urothelium. Bladder Cancer gets worse when it grows into or through other layers of the bladder wall. Over time, the Muscle Invasive bladder cancer may grow outside the bladder into tissues, spreading to lymph nodes, bones, lungs, or liver and other parts of the body. The symptoms of Muscle invasive bladder Cancer (MIBC) are blood in the urine, frequent urination and pain. Blood in the urine (hematuria) is the most common symptom observed in MIBC.

Muscle Invasive Bladder cancer Pipeline Development Activities
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Muscle Invasive Bladder cancer targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Muscle Invasive Bladder cancer pipeline report covers 5+ companies. Some of the key players include Taris Bio (TAR-200), AstraZeneca (Durvalumab) etc.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.

Muscle Invasive Bladder cancer Analytical Perspective by DelveInsight
• In-depth Muscle Invasive Bladder cancer Commercial Assessment of products
This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition –Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.
• Muscle Invasive Bladder cancer Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.
Scope of the report
• The Muscle Invasive Bladder cancer report provides an overview of therapeutic pipeline activity for Muscle Invasive Bladder cancer across the complete product development cycle including all clinical and non-clinical stages
• It comprises of detailed profiles of Muscle Invasive Bladder cancer therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
• Detailed Muscle Invasive Bladder cancer Research and Development progress and trial details, results wherever available, are also included in the pipeline study
• Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
• Coverage of dormant and discontinued pipeline projects along with the reasons if available across Muscle Invasive Bladder cancer

Reasons to Buy
• Establish a comprehensive understanding of the current pipeline scenario across Muscle Invasive Bladder cancer to formulate effective R&D strategies
• Assess challenges and opportunities that influence Muscle Invasive Bladder cancer R&D
• Develop strategic initiatives by understanding the focus areas of leading companies.
• Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Get in detail information of each product with updated information on each project along with key milestones
• Devise Muscle Invasive Bladder cancer in licensing and out licensing strategies by identifying prospective partners with progressing projects for Muscle Invasive Bladder cancer to enhance and expand business potential and scope
• Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs*Please Note:* The report will be delivered in 2 business days upon order confirmation.


1. Report Introduction
2. Muscle Invasive Bladder cancer
2.1. Muscle Invasive Bladder cancer Disease Overview
2.2. Muscle Invasive Bladder cancer History
2.3. Muscle Invasive Bladder cancer Symptoms
2.4. Muscle Invasive Bladder cancer Causes
2.5. Muscle Invasive Bladder cancer Pathophysiology
2.6. Muscle Invasive Bladder cancer Diagnosis
2.6.1. Diagnostic Guidelines
3. Muscle Invasive Bladder cancer Current Treatment Patterns
3.1. Treatment Guidelines
4. Muscle Invasive Bladder cancer- DelveInsight’s Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Muscle Invasive Bladder cancer companies collaborations, Licensing, Acquisition –Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Muscle Invasive Bladder cancer Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Muscle Invasive Bladder cancer Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
4.2.1. Assessment by Phase of Development
4.2.2. Assessment by Product Type (Mono / Combination)
4.2.2.1. Assessment by Stage and Product Type
4.2.3. Assessment by Route of Administration
4.2.3.1. Assessment by Stage and Route of Administration
4.2.4. Assessment by Molecule Type
4.2.4.1. Assessment by Stage and Molecule Type
4.2.5. Assessment by MOA
4.2.5.1. Assessment by Stage and MOA
5. Muscle Invasive Bladder cancer Pipeline Therapeutics
5.1. Late Stage Products (Phase-III)
5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
5.2.1. Comparative Analysis
5.3. Early Stage Products (Phase-I)
5.3.1. Comparative Analysis
5.4. Pre-clinical and Discovery Stage Products
5.4.1. Comparative Analysis
5.5. Inactive Products
6. Muscle Invasive Bladder cancer-Products Analysis
6.1. Product Profiles
6.1.1. TAR-200- Taris Bio
6.1.1.1. Product Description
6.1.1.1.1. Product Overview
6.1.1.1.2. Mechanism of Action
6.1.1.2. Research and Development
6.1.1.2.1. Clinical Studies
6.1.1.2.1.1. Detailed Study Description
6.1.1.2.1.2. Study Results
6.1.1.2.1.3. Clinical Trials: Tabular View
6.1.1.3. Product Development Activities
6.1.1.3.1. Tabulated Product Summary
6.1.1.3.1.1. General Description Table
6.1.2. Durvalumab- AstraZeneca
6.1.2.1. Product Description
6.1.2.1.1. Product Overview
6.1.2.1.2. Mechanism of Action
6.1.2.2. Research and Development
6.1.2.2.1. Clinical Studies
6.1.2.2.1.1. Detailed Study Description
6.1.2.2.1.2. Study Results
6.1.2.2.1.3. Clinical Trials: Tabular View
6.1.2.3. Product Development Activities
6.1.2.3.1. Tabulated Product Summary
6.1.2.3.1.1. General Description Table
To be continued in the report
7. Recent Technologies
8. Muscle Invasive Bladder cancer Key Companies
8.1. AstraZeneca
8.2. Oncolytics Biotech
8.3. Medimmune
8.4. TARIS Biomedical
8.5. Bristol-Myers Squibb
9. Muscle Invasive Bladder cancer Key Products
9.1. Durvalumab
9.2. Pelareorep
9.3. AZD4547
9.4. TAR 200
9.5. Nivolumab
10. Dormant and Discontinued Products
10.1. Dormant Products
10.1.1. Reasons for being dormant
10.2. Discontinued Products
10.2.1. Reasons for the discontinuation
11. Muscle Invasive Bladder cancer- Unmet Needs
12. Muscle Invasive Bladder cancer- Future Perspectives
13. Appendix
14. Report Methodology
14.1. Secondary Research
14.2. Expert Panel Validation
Table 1. Diagnostic Guidelines
Table 2. Treatment Guidelines
Table 3. Assessment Summary
Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5. Muscle Invasive Bladder cancer Acquisition Analysis
Table 6. Assessment by Phase of Development
Table 7. Assessment by Product Type (Mono / Combination)
Table 8. Assessment by Stage and Product Type
Table 9. Assessment by Route of Administration
Table 10. Assessment by Stage and Route of Administration
Table 11. Assessment by Molecule Type
Table 12. Assessment by Stage and Molecule Type
Table 13. Assessment by MOA
Table 14. Assessment by Stage and MOA
Table 15. Late Stage Products (Phase-III)
Table 16. Mid Stage Products (Phase-II)
Table 17. Early Stage Products (Phase-I)
Table 18. Pre-clinical and Discovery Stage Products
Table 19. Inactive Products
Table 20. Dormant Products
Table 21. Discontinued Products
Figure 1. Disease Overview
Figure 2. History
Figure 3. Symptoms
Figure 4. Causes
Figure 5. Pathophysiology
Figure 6. Diagnostic Guidelines
Figure 7. Treatment Guidelines
Figure 8. Muscle Invasive Bladder cancer companies collaborations, Licensing, Acquisition –Deal Value Trends
Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10. Muscle Invasive Bladder cancer Acquisition Analysis
Figure 11. Assessment by Phase of Development
Figure 12. Assessment by Product Type (Mono / Combination)
Figure 13. Assessment by Stage and Product Type
Figure 14. Assessment by Route of Administration
Figure 15. Assessment by Stage and Route of Administration
Figure 16. Assessment by Molecule Type
Figure 17. Assessment by Stage and Molecule Type
Figure 18. Assessment by MOA
Figure 19. Assessment by Stage and MOA
Figure 20. Late Stage Products (Phase-III)
Figure 21. Mid Stage Products (Phase-II)
Figure 22. Early Stage Products (Phase-I)
Figure 23. Pre-clinical and Discovery Stage Products
Figure 24. Inactive Products
Figure 25. Dormant Products
Figure 26. Discontinued Products
Figure 27. Unmet Needs

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report